u/ravi_sandvik

I would not post that as a finding.

Agreed — and two services on one batch is the strongest thing any of us can produce individually.

Careful — that is a question for whoever ordered the panel, and nobody in this thread can answer it responsibly.

Same lab as the previous draw?

Read both programme names carefully after mixing them up in a comment and being politely corrected.

If the report gives a mass spectrum as well as UV purity, say so. Identity and relative quantity are separate claims and the log tracks both.

one result is a data point, agreement between two services is evidence

Milligram comparisons across molecule classes are meaningless.

Agreed, and it is why the oral peptide comparison keeps misleading people.

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

the scale is the least sensitive instrument you own

Tracked ApoB against the weight trend for a year. The correlation was much weaker than I expected and that was worth knowing.

Which trial and which readout?

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

Sceptical of the mechanism you are proposing. Gastric emptying slows, it does not stop, and the timings you describe do not follow from it.

inter-lab variance runs a point or two, plan your outrage accordingly

If the report gives a mass spectrum as well as UV purity, say so. Identity and relative quantity are separate claims and the log tracks both.

Discharge from a specialist service at goal is a normal end point of that pathway.

Adding the practical bit — ask what happens at discharge before you start, not after.

the trend line matters more than any single value

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

staying at 2.4mg for an extra month is a legitimate plan

Yes. Two services on the same batch is the strongest thing an individual member can produce, and it is not expensive.

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

sema is weekly for a reason, the half-life does the smoothing

do not chase somebody else’s titration schedule, they are not you

nothing here is approved as a standalone product and research material is not for human use

The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.

the scale is the least sensitive instrument you own

The appetite thing was the surprise. I expected to feel full. What I got was simply not thinking about food between meals.

Genuine question — is the appetite effect still there, or is it just the scale that has paused?

sulphur burps made the first fortnight rough at each step up, then flattened out. Predictable enough that I started planning around it.

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

Disagree with this specific line.

This is the part I would underline for anyone skimming. Everything else in the thread is downstream of it.

That reads like a titration plan and this board cannot give you one. Somebody who actually knows your history has to.

Is that from the publication or the press release?

Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.

identity testing on a small molecule is a different analytical problem

Disagree that this is a discrepancy. 98.3% against a claimed 97.5% is inside ordinary inter-lab variance in either direction.

Pharmacy pricing on a private prescription is set by the pharmacy. The spread between them in a given month is routinely substantial, which is why a tracker built from member reports is more useful than any headline.

Agreed on assay changes. A lab switching platforms between your draws is invisible unless you ask.

lab reference ranges are not treatment targets